HM Payson & Co’s Lexicon Pharmaceuticals LXRX Stock Holding History

HM Payson & Co’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89	Hold	37	–	–	﹤0.01%	1129
2026 Q1	$58	Buy	+37	New	+$54	﹤0.01%	1119

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HM Payson & Co's LXRX Position: Q2 2026 in Review

HM Payson & Co held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 37 shares worth $89. The position accounts for ﹤0.01% of the portfolio, ranked #1129.

HM Payson & Co first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

HM Payson & Co held 37 shares of Lexicon Pharmaceuticals worth $89 as of Q2 2026.
HM Payson & Co left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
Lexicon Pharmaceuticals made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #1129 holding.
HM Payson & Co first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.